IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Abroad (travel likely)RecruitingPHASE2
Conditions
Ovarian Cancer Recurrent
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cancer Hospital Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
Contact: Study coordinator (Lingying WU)
Study leads
Lingying WU
Principal Investigator
Cancer Hospital Chinese Academy of Medical Science and Peking Union Medical College